Jazz Pharmaceuticals plc completed the divestiture of Sunosi (solriamfetol) in the United States. to Axsome Therapeutics Inc.

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals’ Xywav for idiopathic hypersomnia in adults.

Jazz Pharmaceuticals is beefing up its neurology pipeline with a $7.2 billion buyout of GW Pharmaceuticals, the only company yet to score U.S. regulatory approval for a cannabis-derived product.

Jazz Pharmaceuticals Plc’s treatment for a form of sleep disorder was recommended for approval by a panel of the European Medicines Agency (EMA).

Harmony Biosciences snagged approval from the U.S. FDA for the company’s first commercial product, a treatment for narcolepsy.

Obstructive sleep apnea (OSA) may affect as much as 37 percent of adults in North, Central and South America, according to a review of epidemiological studies.

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder.

Google’s Verily will team up with ResMed, a company that specializes in treating sleep disorders, to launch a joint business venture to address sleep apnea and other sleeping disorders.

A recently released study from a team led by Morehouse School of Medicine shows that the process controlling sleep may not lie totally in the brain.

206 million American adults struggling to get a good night’s rest seek out sleep management solutions to deal with conditions such as insomnia, sleep apnea, narcolepsy, and more.